Xencor News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

18.04.18	Xencor Presents Preclinical Data on XmAb®24306, Introduces XmAb® IL15 Bispecific Platform at American Association for Cancer Research (AACR) 2018 Annual Meeting (PR Newswire)
21.03.18	Xencor to Present at 17th Annual Needham Healthcare Conference (PR Newswire)
20.03.18	ARNA Soars After-hours, Remoxy Now 2 Steps Away From Approval, APLS On Watch (RTTNews)
27.02.18	Xencor Reports Fourth Quarter and Full Year 2017 Financial Results (PR Newswire)
27.02.18	Disney Announces Transformative Multi-Year Expansion for Disneyland Paris (PR Newswire)
22.02.18	Xencor Doses First Patient in Phase 1 Study of XmAb®18087 Bispecific Tumor Targeting Antibody for the Treatment of Neuroendocrine Tumors and Gastrointestinal Stromal Tumors (PR Newswire)
20.02.18	Xencor to Host Fourth Quarter and Full Year 2017 Financial Results Webcast and Conference Call on February 27, 2018 (PR Newswire)
07.02.18	Xencor to Present at Upcoming Investor Conferences (PR Newswire)
05.01.18	Xencor Announces 2018 Priorities and Expected Milestones (PR Newswire)
19.12.17	Xencor Appoints Richard Ranieri to Board of Directors (PR Newswire)
05.12.17	Xencor Receives Milestone Payment from Amgen (PR Newswire)
08.11.17	Xencor to Present Preclinical Data on Tumor Microenvironment Targeting Bispecifics XmAb®20717 and XmAb®23104 at Society for Immunotherapy of Cancer (SITC) 2017 Annual Meeting (PR Newswire)
07.11.17	Xencor Reports Third Quarter 2017 Financial Results and Provides Clinical Pipeline Update (PR Newswire)
06.11.17	FDA Ruling On DVAX This Week, XNCR On Watch, It's Impressive But Early For AVXL (RTTNews)
05.11.17	Xencor Presents Final Results from Phase 2 Study of XmAb®5871 in IgG4-Related Disease (IgG4-RD) at the American College of Rheumatology 2017 Annual Meeting (PR Newswire)
01.11.17	Xencor to Present at Upcoming Investor Conferences (PR Newswire)
31.10.17	Xencor to Host Third Quarter 2017 Financial Results Webcast and Conference Call on November 7, 2017 (PR Newswire)
23.10.17	DBVT Disappoints, GSK Gets Greenlight, AIMT Catches Eyes, FDA Snubs ATRS (RTTNews)
20.10.17	Xencor to Present Final Results from Phase 2 Study of XmAb®5871 in IgG4-Related Disease at American College of Rheumatology (ACR) 2017 Annual Meeting (PR Newswire)
20.09.17	Xencor to Present at Upcoming Investor Conferences (PR Newswire)
07.08.17	Xencor Reports Second Quarter 2017 Financial Results (PR Newswire)
02.08.17	Xencor to Present at Upcoming Investor Conferences (PR Newswire)
31.07.17	Xencor to Host Second Quarter 2017 Financial Results Webcast and Conference Call on August 7, 2017 (PR Newswire)
19.06.17	FDA Nod For Ipsen, XNCR On Watch, Results MAGINIFY CELG's R2 Regimen (RTTNews)
16.06.17	Xencor Presents Interim Data from an Ongoing, Open-label, Phase 2 Study of XmAb®5871 in IgG4-Related Disease at EULAR 2017 (PR Newswire)
08.06.17	Xencor Appoints Raphael Clynes, M.D., Ph.D., as Vice President of Translational Biology (PR Newswire)
30.05.17	Xencor to Present at Jefferies 2017 Global Healthcare Conference (PR Newswire)
12.05.17	AKTX Falls To Disgrace, CATB Awaits Data In Q3, CORI Surges On Trial Data (RTTNews)
11.05.17	Xencor's Lead Drug Candidate, XmAb5871, Receives Orphan Drug Designation from FDA for Treatment of IgG4-Related Disease (PR Newswire)
09.05.17	Xencor Reports First Quarter 2017 Financial Results (PR Newswire)
26.04.17	Xencor to Present at 42nd Annual Deutsche Bank Health Care Conference (PR Newswire)
17.04.17	Xencor Appoints Kevin Gorman, Ph.D., to its Board of Directors (PR Newswire)
15.03.17	Xencor to Present at Oppenheimer 27th Annual Healthcare Conference (PR Newswire)
06.03.17	Xencor Announces Bruce L.A. Carter, Ph.D., Chairman of the Board of Directors, Will Not Stand for Reelection to Board of Directors at 2017 Annual Meeting of Stockholders (PR Newswire)
01.03.17	Xencor Presents Preclinical Data on Emerging Bispecific Antibody Candidates at American Association for Cancer Research (AACR) 2017 Annual Meeting (PR Newswire)
22.02.17	Xencor to Host Fourth Quarter and Full Year 2016 Financial Results Webcast and Conference Call on February 28, 2017 (PR Newswire)
18.02.17	IgG4-Related Disease Biomarker Development Update Presented From an Ongoing, Open-label, Phase 2 Study of XmAb®5871 in IgG4-RD at the 3rd International Symposium on IgG4-Related Diseases & Fibrosis (PR Newswire)
09.02.17	Xencor to Present at Leerink Partners 6th Annual Global Healthcare Conference (PR Newswire)
06.12.16	Xencor, Inc. Announces Completion of Public Offering of Common Stock and Exercise in Full of Option to Purchase Additional Shares of Common Stock (PR Newswire)
01.12.16	Xencor, Inc. Prices Public Offering of Common Stock (PR Newswire)
30.11.16	Xencor, Inc. Announces Proposed Public Offering of Common Stock (PR Newswire)
29.06.16	ANTH Dims On BRIGHT-SC Data, CYAD Fails To Chart, LLY Gets FDA Panel Nod (RTTNews)
28.06.16	Xencor, Novartis In Collaboration, License Deal For Bispecific Antibodies (RTTNews)
03.05.16	Northwest Bio Heading North, PRTK To Report Data In June, FLML Gets FDA Nod (RTTNews)
08.03.16	Interesting Stocks To Watch: March 8 (RTTNews)
08.03.16	ACRX For The Long Haul, CLDX Disappoints, NVIV Inspires, MRNS Awaits Data (RTTNews)
16.09.15	Amgen & Xencor Announce Research Collaboration - Quick Facts (RTTNews)
07.12.14	MorphoSys, Xencor Publish Phase 1/2a Trial's Final Results Of MOR208 In CLL/SLL (RTTNews)
11.11.14	AMGN Gets FDA Date, TTPH On Track, SAGE Keeps Calm, Busy Months Ahead For XNCR (RTTNews)
01.08.14	ALXA Working Its Way, CERS Awaits FDA Decision, XNCR, SGEN Look Ahead To Results (RTTNews)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Givaudan	4’040.00	1.71 %	K V
Geberit	547.80	1.59 %	K V
Part Grp Hldg	1’297.00	1.49 %	K V
ABB	51.94	1.29 %	K V
Swiss Life Hldg	691.80	1.26 %	K V
Zurich Insur Gr	548.00	-0.18 %	K V
Kuehne+Nagel Int	210.90	-0.33 %	K V
Swiss Re	128.20	-0.66 %	K V
Sonova Hldg	293.00	-0.85 %	K V
Novartis	87.94	-0.92 %	K V

Nachrichten zu Xencor Inc

Aktien Top/Flop

Meistgelesene Nachrichten